136 related articles for article (PubMed ID: 35673726)
21. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
[TBL] [Abstract][Full Text] [Related]
22. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D; Yao J; Yang F; Huo L; Chen H; Lu W; Soto LMS; Jiang M; Raso MG; Wang S; Bell D; Liu J; Wang H; Tan D; Torres-Cabala C; Gan Q; Wu Y; Albarracin C; Hung MC; Meric-Bernstam F; Wistuba II; Prieto VG; Sahin AA; Ding Q
Mod Pathol; 2021 Apr; 34(4):710-719. PubMed ID: 33011748
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
26. The Utility of SOX10 Immunohistochemical Staining in Breast Pathology.
Rammal R; Goel K; Elishaev E; Rinda Soong T; Jones MW; Zhao C; Clark BZ; Carter GJ; Yu J; Fine JL; Villatoro TM; Harinath L; Bhargava R
Am J Clin Pathol; 2022 Nov; 158(5):616-625. PubMed ID: 36000970
[TBL] [Abstract][Full Text] [Related]
27. Role of SOX10 Immunohistochemical Expression in Diagnosing Triple Negative Breast Cancer and Its Correlation With Clinicopathological Features.
Tariq MU; Siddiqui MA; Ud Din N; Kayani N
Cureus; 2024 Apr; 16(4):e59276. PubMed ID: 38813332
[TBL] [Abstract][Full Text] [Related]
28. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
[TBL] [Abstract][Full Text] [Related]
29. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
[TBL] [Abstract][Full Text] [Related]
30. Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis.
Chien ST; Yang TF; Yang MC; Hsu CM; Hong YR; Lee TM
Oncol Rep; 2015 Aug; 34(2):961-71. PubMed ID: 26082034
[TBL] [Abstract][Full Text] [Related]
31. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
32. Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples.
Lynn TJ; Shi J; Liu H; Monaco SE; Prichard JW; Lin F
Arch Pathol Lab Med; 2024 Jan; 148(1):e1-e8. PubMed ID: 37406296
[TBL] [Abstract][Full Text] [Related]
33. S-100 protein and SOX10-positive breast carcinoma mimicking metastatic melanoma.
Newman J; Brahmbhatt M; Stoff BK; Martinez AP
J Cutan Pathol; 2020 Dec; 47(12):1187-1191. PubMed ID: 32710508
[TBL] [Abstract][Full Text] [Related]
34. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
35. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
36. SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.
Adkins BD; Geromes A; Zhang LY; Chernock R; Kimmelshue K; Lewis J; Ely K
Head Neck Pathol; 2020 Jun; 14(2):406-411. PubMed ID: 31222589
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.
Ivanov SV; Panaccione A; Nonaka D; Prasad ML; Boyd KL; Brown B; Guo Y; Sewell A; Yarbrough WG
Br J Cancer; 2013 Jul; 109(2):444-51. PubMed ID: 23799842
[TBL] [Abstract][Full Text] [Related]
38. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
39. Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Kriegsmann K; Flechtenmacher C; Heil J; Kriegsmann J; Mechtersheimer G; Aulmann S; Weichert W; Sinn HP; Kriegsmann M
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899175
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
